mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors - PubMed (original) (raw)

Affiliations

PMID: 11123360

mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors

V A Movsesyan et al. J Pharmacol Exp Ther. 2001 Jan.

Abstract

The effect of selective group I metabotropic glutamate receptor subtype 5 (mGluR5) antagonists 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and (E)-2-methyl-6-(2-phenylethenyl)-pyridine (SIB-1893) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. Treatment with MPEP and SIB-1893 showed significant neuroprotective effects in rat cortical neuronal cultures subjected to mechanical injury. Application of the antagonists also attenuated glutamate- and N-methyl-D-aspartate (NMDA)-induced neuronal cell death in vitro. Intracerebroventricular administration of MPEP to rats markedly improved motor recovery and reduced deficits of spatial learning after lateral fluid percussion-induced traumatic brain injury. Lesion volumes as assessed by magnetic resonance imaging were also substantially reduced by MPEP treatment. Although we show that MPEP acts as a potent mGluR5 antagonist in our culture system, where it completely blocks agonist-induced phosphoinositide hydrolysis, electrophysiological and pharmacological studies indicate that MPEP and SIB-1893 also inhibit NMDA receptor activity at higher concentrations that are neuroprotective. Taken together, these data suggest that MPEP and SIB-1893 may have therapeutic potential in brain injury, although the mechanisms of neuroprotective action for these drugs may reflect their ability to modulate NMDA receptor activity.

PubMed Disclaimer

Cited by

Amyloid-β Causes NMDA Receptor Dysfunction and Dendritic Spine Loss through mGluR1 and AKAP150-Anchored Calcineurin Signaling.
Prikhodko O, Freund RK, Sullivan E, Kennedy MJ, Dell'Acqua ML. Prikhodko O, et al. J Neurosci. 2024 Sep 11;44(37):e0675242024. doi: 10.1523/JNEUROSCI.0675-24.2024. J Neurosci. 2024. PMID: 39134419
Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.
Montana MC, Gereau RW. Montana MC, et al. Curr Pharm Biotechnol. 2011 Oct;12(10):1681-8. doi: 10.2174/138920111798357438. Curr Pharm Biotechnol. 2011. PMID: 21466446 Free PMC article. Review.
Metabotropic glutamate receptor 5 deficiency inhibits neutrophil infiltration after traumatic brain injury in mice.
Yang T, Liu YW, Zhao L, Wang H, Yang N, Dai SS, He F. Yang T, et al. Sci Rep. 2017 Aug 30;7(1):9998. doi: 10.1038/s41598-017-10201-8. Sci Rep. 2017. PMID: 28855570 Free PMC article.
Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.
Caprioli D, Justinova Z, Venniro M, Shaham Y. Caprioli D, et al. Biol Psychiatry. 2018 Aug 1;84(3):180-192. doi: 10.1016/j.biopsych.2017.08.018. Epub 2017 Sep 5. Biol Psychiatry. 2018. PMID: 29102027 Free PMC article. Review.
The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway.
Chen T, Zhang L, Qu Y, Huo K, Jiang X, Fei Z. Chen T, et al. Int J Mol Med. 2012 Apr;29(4):630-6. doi: 10.3892/ijmm.2011.870. Epub 2011 Dec 28. Int J Mol Med. 2012. PMID: 22211238 Free PMC article.

mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors - PubMed (original) (raw)